RET targeted treatment of medullary thyroid carcinoma
- VernacularTitle:以RET为靶点治疗甲状腺髓样癌
- Author:
Huiying JIA
- Publication Type:Journal Article
- Keywords:
Thyroid neoplasms;
Therapy;
RET proto-oncogenes
- From:
Journal of International Oncology
2008;35(10):764-767
- CountryChina
- Language:Chinese
-
Abstract:
Medullary thyroid carcinoma(MTC), which includes sporadic type and hereditary type, is a kind of malignant tumor in thyroid parafollicular cells. MTC is the common clinical character of the multiple en-docrine neoplasia type 2 (MEN 2), including MEN 2A and MEN 2B, and familial medullary thyroid carcinoma(FMTC). The RET gene encodes a receptor tyrosine kinase, its mutations and polymorphisms can induce acti-vation of the BET tyrosine kinase domain via different signal pathways resulting the genesis of MTC. RET has been used as a target for MTC molecular therapy. However, a clinically useful therapeutic option for treating pa-tients with RET-associated cancer is still not available.
